Edgar Filing: Karyopharm Therapeutics Inc. - Form 4

Karyopharm Therapeutics Inc. Form 4 May 27, 2016 OMB APPROVAL FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES OMB APPROVAL Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, ection 17(a) of the Public Utility Holding Company Act of 1935 or Section 1(b). Expires: 30(h) of the Investment Company Act of 1940 State average burden hours per response								3235-0287 January 31, 2005 verage	
(Print or Type Responses)									
1. Name and Ad Chione Ltd	Symbol	Symbol Is Karyopharm Therapeutics Inc.				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) SIMOU ME COURT 8, C	(Month/D	3. Date of Earliest Transaction(Month/Day/Year)05/25/2016				Director Officer (give title Other (specify below)			
6015 LARN	(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person X_ Form filed by More than One Reporting 				
(City)		Zip) Tabl	a L. Nam D	: 6	· · · · · ·		rson	Donoff of all	O d
1.Title of Security (Instr. 3)	2. Transaction Date	1 401	3. Transacti Code (Instr. 8)	4. Securit oror Dispos (Instr. 3, 4	ies Ac ed of (4 and 3 (A) or	equired (A) (D) (5)	ed, Disposed of, of 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
COMMON STOCK	05/25/2016		Code V S	Amount 27,940	(D) D	Price \$ 9.8261 (1) (2)	(11547 + 5414 + 5) 8,772,060 (3) (4) (5)	D	
COMMON STOCK	05/26/2016		S	18,182	D	\$ 9.5857 (<u>1)</u> (<u>2)</u>	8,753,878 <u>(3)</u> (4) (5)	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

Edgar Filing: Karyopharm Therapeutics Inc. - Form 4

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transact Code (Instr. 8)	5. ionNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3,	iumber Expiration Date (Month/Day/Year) verivative ecurities ccquired A) or tisposed f (D)		7. Titl Amou Under Secur (Instr.	ınt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
			Code V	4, and 5)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Chione Ltd SIMOU MENARDOU 8 RIA COURT 8, OFFICE 101 6015 LARNACA, G4		Х				
Czernik Marcin SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101 6015 LARNACA, G4		Х				
Hadjimichael Andreas SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101 6015 LARNACA, G4		Х				
Hadjimichael George SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101 6015 LARNACA, G4		Х				
Smolokowski Wiaczeslaw CHALET LENOTCHKA CH.DE BARNOUD 1885 CHESIERES SWITZERLAND, G4 00000		Х				

Signatures

/s/ Chione Limited, by /s/ Simon Prisk, as attorney-in fact by power of attorney					
**Signature of Reporting Person	Date				
/s/ Marcin Czernik, by /s/ Simon Prisk, as attorney-in fact by power of attorney					
**Signature of Reporting Person	Date				
/s/ Andreas Hadjimichael, by /s/ Simon Prisk, as attorney-in fact by power of attorney					
**Signature of Reporting Person	Date				
/s/ George Hadjimichael, by /s/ Simon Prisk, as attorney-in fact by power of attorney					
**Signature of Reporting Person	Date				
/s/ Wiaczeslaw Smolokowski, by /s/ Simon Prisk, as attorney-in fact by power of					
attorney	05/27/2016				
**Signature of Reporting Person	Date				

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The prices reported in Column 4 are weighted average prices. The 27,940 shares referred to in the first row of Column 4 were sold at prices ranging from \$9.67 to \$10.12, inclusive. The 18,182 shares referred to in the second row of Column 4 were sold at prices ranging from \$9.50 to \$9.64, inclusive.
- The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange
 (2) Commission, upon request, full information regarding the number of shares sold at each separate price within each of the ranges set forth in footnote 1 above.

(3) Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas
 (3) Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione.

(4) Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed, except, with respect to any person, to the extent of the pecuniary interest of such person in such securities.

(5) Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.

Remarks:

Exhibit Index Exhibit 24.1 - Power of Attorney, dated May 12, 2016, made by Marcin Czernik and Chione Limited in favor of

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.